Key points are not available for this paper at this time.
What is this summary about? This is a summary of a paper published in The Lancet medical journal describing the results of the NefIgArd clinical trial, which looked at Nefecon treatment in people with immunoglobulin A nephropathy (IgAN). IgAN is a kidney disease caused by a special type of antibody called galactosedeficient immunoglobulin A (gd-IgA), which collects in the kidneys. This triggers inflammation (which is the body fighting disease) and damages the kidneys over time (nephropathy), often leading to kidney failure. Nefecon is a new pill containing a medicine called budesonide and acts in the lower part of the small intestine, where the IgAN disease process is thought to start.
Lafayette et al. (Wed,) studied this question.